Skip to content

IEMbase 0262: Alpha-N-acetylgalactosaminidase deficiency, Schindler disease type I

Scope

Field Value
IEMbase ID 262
Nosology 20.3.05.01
Gene NAGA
External IDs OMIM:609241; ORPHA:79281
Generated mapping MAPPED; NAGA_Deficiency_Type_3.yaml
Candidate DisMech targets Schindler_Disease.yaml; NAGA_Deficiency_Type_3.yaml
Review date 2026-07-07

IEMbase phenotype signal

IEMbase represents this as alpha-N-acetylgalactosaminidase deficiency with alternate labels Schindler disease type I and NAGA. The record is autosomal recessive and treatability is marked unknown, with no treatment rows in the cached JSON.

Biochemical rows include decreased alpha-N-acetylgalactosaminidase activity in fibroblasts and white blood cells, plus increased urinary N-acetylgalactosaminyl-oligosaccharides. Clinical rows include ataxia, neuroaxonal dystrophy, and exaggerated startle response.

DisMech phenotype coverage

Schindler_Disease.yaml is the correct local target. The local entry defines Schindler disease as alpha-N-acetylgalactosaminidase deficiency type 1, the severe infantile neuroaxonal-dystrophy form of NAGA deficiency. It covers biallelic NAGA variants, loss of lysosomal alpha-N-acetylgalactosaminidase, glycopeptide/glycoconjugate accumulation, urinary glycopeptide excretion, developmental regression, hypotonia, spasticity, areflexia, blindness, hearing impairment, CNS axonal spheroids, and supportive care.

NAGA_Deficiency_Type_3.yaml is not the right canonical target for this IEMbase record because it represents Schindler disease type III, the intermediate phenotype.

Concordance and completeness

Judgement: generated mapping is a false positive to type 3; resolve to Schindler_Disease.yaml.

IEMbase and the local Schindler disease entry agree on NAGA/type I identity, alpha-N-acetylgalactosaminidase deficiency, urinary oligosaccharide or glycopeptide storage signal, autosomal recessive inheritance, and neuroaxonal dystrophy. IEMbase adds ataxia and exaggerated startle response as compact phenotype prompts. The generated type 3 target shares the enzyme defect but is the wrong severity/type entity.

Curation actions

  • Remap this record to Schindler_Disease.yaml.
  • Do not use NAGA_Deficiency_Type_3.yaml as the canonical target for Schindler disease type I.
  • Use IEMbase's ataxia and exaggerated-startle rows as phenotype review prompts for the Schindler type I entry.